Pfizer of the United States will apply to the British health regulator for emergency use authorization to vaccinate young people with the Pfizer-BioNTech coronavirus vaccine.
A Pfizer spokesperson confirmed to Reuters via email on Tuesday (11th) that the company has submitted its coronavirus vaccine data for people aged 12 to 15 to the British Medicines and Healthcare Products Regulatory Agency (MHRA).
The US Food and Drug Administration has just approved this vaccine for 12 to 15-year-olds the day before.
Pfizer said in March that the company’s clinical trials on 2,260 adolescents showed that the Pfizer-BioNTech vaccine is safe and effective, generating a strong antibody response in people aged 12 to 15 and preventing covid-19 by 100%.
Pfizer expects to release data on vaccine safety and vaccine efficacy for children aged 2 to 11 years old in September and will apply to the United States for emergency use authorization to vaccinate children of this age.